Calendar Year Performance 2014Calendar Year Performance 2015Calendar Year Performance 2016Calendar Year Performance 2017Calendar Year Performance 2018Calendar Year Performance 2019Calendar Year Performance 2020Calendar Year Performance 2021Calendar Year Performance 2022Calendar Year Performance 2023
-
-
-
-
-
-
-
-
- 19.5 %
+ 20.7 %
Net Asset Value
108.24 £
Asset Under Management
533 M €
Market
Global market
SFDR - Fund Classification
Article
9
Data as of: 30 Sep 2024.
Data as of: 5 Nov 2024.
Past performance is not necessarily indicative of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor). The Sustainable Finance Disclosure Regulation (SFDR) 2019/2088 is a European regulation that requires asset managers to classify their funds as either 'Article 8' funds, which promote environmental and social characteristics, 'Article 9' funds, which make sustainable investments with measurable objectives, or 'Article 6' funds, which do not necessarily have a sustainability objective. For more information please refer to https://eur-lex.europa.eu/eli/reg/2019/2088/oj.
Major indices reached all-time highs during the month, driven by monetary easing from central banks.
Chinese equities surged towards the end of the period as Beijing's stimulus measures boosted optimism about the recovery of the world's second-largest economy. These measures aim to counter monetary contraction, address the collapse in the property market, and revive the struggling stock market.
The Federal Reserve initiated its easing cycle with an aggressive 50 basis point cut in its key rate, while the European Central Bank continued to reduce its key rates by 25 basis points.
Economic indicators in the United States remain robust, with rising retail sales and industrial production, a mixed but solid employment market, and falling inflation. In contrast, economic activity in the eurozone has been more lackluster.
Performance commentary
The Fund underperformed its reference inidcator over the month.- Our equities portfolio was negatively impacted by the poor monthly performance of Novo Nordisk. The stock declined following the presentation of mixed phase 2a clinical data on its new experimental treatment for obesity, Monlunabant.- The Fund was also affected by our other long-term holdings in the healthcare sector, including Vertex, Genmab, and Demant.- Our underexposure to consumer discretionary stocks, in favor of consumer staples, prevented us from capitalizing on the sector's rise due to announcements from the Chinese government.- Conversely, our high-quality technology stocks performed well, as demonstrated by the strong performance of SAP, Microsoft, and Oracle, which reported good results, particularly in terms of demand for their cloud infrastructure services.
Outlook strategy
In line with our strategy, we remain cautious and favor defensive-quality companies in the context of a global economic slowdown. However, we have made a few adjustments to the portfolio.- Firstly, we have slightly increased our exposure to technology stocks, which have suffered in recent months, particularly in the semiconductor sector. - These increases were financed by profit-taking in companies that have performed well over the past 12 months, such as P&G, Colgate, and S&P Global.- Finally, we took advantage of the rebound in consumer discretionary stocks following the Chinese announcements to sell our remaining stake in Estée Lauder.
Reference to certain securities and financial instruments is for illustrative purposes to highlight stocks that are or have been included in the portfolios of funds in the Carmignac range. This is not intended to promote direct investment in those instruments, nor does it constitute investment advice. The Management Company is not subject to prohibition on trading in these instruments prior to issuing any communication. The portfolios of Carmignac funds may change without previous notice.
The reference to a ranking or prize, is no guarantee of the future results of the UCIS or the manager.
The information presented above is not contractually binding and does not constitute investment advice. Past performance is not a reliable indicator of future performance. Performance is shown net of fees (excluding any subscription fees payable to the distributor). Investors may lose some or all of their capital, as the capital in the UCI is not guaranteed. Access to the products and services presented herein may be restricted for some individuals or countries. Taxation depends on the situation of the individual. The risks, fees and recommended investment period for the UCI presented are detailed in the KIDs (key information documents) and prospectuses available on this website. The KID must be made available to the subscriber prior to purchase.
Carmignac Portfolio is a sub-fund of Carmignac Portfolio SICAV, an investment company under Luxembourg law, conforming to the UCITS Directive.
Unsupported browserWe've noticed that your browser is no longer supported. To ensure optimal performance and security while using our website, we recommend updating your browser or other relevant software. Thank you for your understanding!
Market environment
Major indices reached all-time highs during the month, driven by monetary easing from central banks.
Chinese equities surged towards the end of the period as Beijing's stimulus measures boosted optimism about the recovery of the world's second-largest economy. These measures aim to counter monetary contraction, address the collapse in the property market, and revive the struggling stock market.
The Federal Reserve initiated its easing cycle with an aggressive 50 basis point cut in its key rate, while the European Central Bank continued to reduce its key rates by 25 basis points.
Economic indicators in the United States remain robust, with rising retail sales and industrial production, a mixed but solid employment market, and falling inflation. In contrast, economic activity in the eurozone has been more lackluster.